BENNETT C FRANK 4

What Happened Bennett C. Frank, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), sold a total of 20,536 shares in open-market transactions on July 7, 2026 under a pre-established Rule 10b5-1 plan, generating approximately $1,744,623 in proceeds. The filing also reports the acquisition of 15,000 shares (resulting from a vested restricted stock unit) and a separate transfer of 15,000 shares into a family trust (reclassification to indirect ownership).

Key Details

• Transaction date: July 7, 2026; Form 4 filed July 9, 2026 (no late filing indicated).
• Sales:
  • 5,536 shares sold at a weighted-average price of $83.58 (reported range $83.070–$84.065) — proceeds $462,693. (Footnote F2)
  • 15,000 shares sold at a weighted-average price of $85.46 (reported range $85.015–$85.730) — proceeds $1,281,930. (Footnote F4)
  • Combined open-market proceeds ≈ $1,744,623.
• Other transactions:
  • 15,000 shares recorded as acquired at $0 (RSU vested; paid out in shares) — footnote F5.
  • 15,000 shares transferred from direct to indirect ownership held by the Clarence Frank Bennett TTEE Bennett Living Trust (reporting-person is co-trustee) — footnote F3 (J code, $0 disposition/reclassification).
• Sales were made pursuant to a Rule 10b5-1 trading plan adopted March 31, 2026 (footnote F1).
• Shares owned after the transactions are not specified in the excerpt of the Form 4 provided.

Context

• Sales under a 10b5-1 plan are pre-arranged and routine; they do not necessarily reflect a change in insider sentiment.
• The 15,000-share acquisition was a vested RSU payout (non-cash compensation). The simultaneous transfer to a trust is a change in ownership classification, not a market sale.
• For retail investors, outright purchases generally carry more direct informational value than routine sales; these entries should be viewed as reporting of compensation realization and portfolio/estate reorganization rather than a clear buy/sell signal.